1. Home
  2. AVDL vs ETWO Comparison

AVDL vs ETWO Comparison

Compare AVDL & ETWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • ETWO
  • Stock Information
  • Founded
  • AVDL 2015
  • ETWO 2000
  • Country
  • AVDL Ireland
  • ETWO United States
  • Employees
  • AVDL N/A
  • ETWO N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • ETWO EDP Services
  • Sector
  • AVDL Health Care
  • ETWO Technology
  • Exchange
  • AVDL Nasdaq
  • ETWO Nasdaq
  • Market Cap
  • AVDL 764.3M
  • ETWO 727.0M
  • IPO Year
  • AVDL 1996
  • ETWO N/A
  • Fundamental
  • Price
  • AVDL $7.91
  • ETWO $2.25
  • Analyst Decision
  • AVDL Strong Buy
  • ETWO Sell
  • Analyst Count
  • AVDL 7
  • ETWO 4
  • Target Price
  • AVDL $18.86
  • ETWO $3.28
  • AVG Volume (30 Days)
  • AVDL 1.5M
  • ETWO 863.0K
  • Earning Date
  • AVDL 03-03-2025
  • ETWO 04-28-2025
  • Dividend Yield
  • AVDL N/A
  • ETWO N/A
  • EPS Growth
  • AVDL N/A
  • ETWO N/A
  • EPS
  • AVDL N/A
  • ETWO N/A
  • Revenue
  • AVDL $169,117,000.00
  • ETWO $613,459,000.00
  • Revenue This Year
  • AVDL $51.49
  • ETWO N/A
  • Revenue Next Year
  • AVDL $32.18
  • ETWO $1.84
  • P/E Ratio
  • AVDL N/A
  • ETWO N/A
  • Revenue Growth
  • AVDL 504.79
  • ETWO N/A
  • 52 Week Low
  • AVDL $7.39
  • ETWO $2.11
  • 52 Week High
  • AVDL $19.09
  • ETWO $5.08
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 43.28
  • ETWO 35.36
  • Support Level
  • AVDL $7.45
  • ETWO $2.11
  • Resistance Level
  • AVDL $7.97
  • ETWO $2.41
  • Average True Range (ATR)
  • AVDL 0.37
  • ETWO 0.10
  • MACD
  • AVDL -0.01
  • ETWO -0.02
  • Stochastic Oscillator
  • AVDL 33.82
  • ETWO 24.11

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About ETWO E2open Parent Holdings Inc.Class A

E2open Parent Holdings Inc is an end-to-end and cloud-based supply chain management SaaS platform. The company's software combines networks, data, and applications to provide a deeply embedded, mission-critical platform that allows customers to optimize the supply chain across channel shaping, business planning, logistics, trade, manufacturing, and supply management. The Group has one reportable segment consisting of cloud-based, end-to-end SCM software. Geographically, the company operates in the Americas, Europe, and Asia Pacific, out of which the majority is from the Americas.

Share on Social Networks: